[1] 徐桂芳,张伟杰,周志华,等.肿瘤干细胞与多药耐药[J].国际肿瘤学杂志,2012,39(12):902-904.[2] 李星,刘鹏,谢小明.乳腺癌靶向治疗进展[J].临床外科杂志,2013, 21(7):559-562.[3] Wu S, Wen F, Li Y, et al. PIK3CA and PIK3CB silencing by RNAi reverse MDR and inhibit tumorigenic properties in human colorectal carcinoma. Tumour Biol. 2016;37(7):8799- 8809.[4] 吴玉强,薛文翰.中药逆转白血病细胞多药耐药的研究进展[J].甘肃医药,2016,35(4):267-269.[5] 史曦凯,张翼军,赵春景.人参皂甙单体Rb1对多药耐药细胞系K562/HHT的耐药逆转作用[J].第三军医大学学报,1999,21(11): 825-827.[6] 韩晓红,盖晓东,薛延军,等.柴胡提取物对人肝癌细胞BEL-7402细胞内游离钙离子浓度和细胞内VCR蓄积的影响[J].肿瘤,2006, 26(4):314-317.[7] 任思璇.中药逆转肿瘤多药耐药的潜力[J].中药与临床,2012, 3(5):57-60.[8] 刘桦,白焱晶,陈亚云,等.中药补骨脂化学成分的研究[J].中国中药杂志,2008,33(12):1410-1412.[9] 孙洪光,杨振林,程凯,等.CD44+CD24-/low乳腺癌干细胞分选鉴定及其多药耐药性研究[J].中华肿瘤防治杂志,2013,20(12): 891-893.[10] 赵万忠,程凯,王晓红,等.补骨脂素对乳腺癌耐药细胞株周期和细胞凋亡的影响[J].中华临床医师杂志(电子版),2016, 40(14): 2111-2115.[11] 陈炬莹,陈晓耕.乳腺癌干细胞富集方法的初步研究[J].福建医药杂志,2015,37(2):80-82, 141.[12] 殷云杰,严金川,王中群,等.CD137信号通过核因子κB影响小鼠主动脉平滑肌细胞活化T细胞核因子c1表达[J].中华心血管病杂志,2015,43(7):614-618.[13] Tysnes BB, Bjerkvig R. Cancer initiation and progression: involvement of stem cells and the microenvironment. Biochim Biophys Acta. 2007;1775(2):283-297. [14] 王文廉.基于乳腺癌干细胞的临床治疗进展[J].中外健康文摘, 2013(31):120.[15] Phillips TM, McBride WH, Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst. 2006;98(24):1777-1785.[16] 屈洪波,范原铭,韩明利,等.化疗后残存乳腺癌组织中乳腺癌耐药蛋白、P-糖蛋白的表达及其与癌干细胞的相关性[J].中国医学科学院学报,2013,35(2):171-176.[17] 张书卿,张博,洪亮,等.乳腺癌干细胞培养鉴定及分化过程中微环境的影响[J].中国组织工程研究,2015,19(14):2155-2160.[18] 季平.肿瘤干细胞研究进展及展望[J].重庆医学,2007,36(4): 289-290.[19] 翟晓建,张浩,张旖旎,等.CD44+CD24-/low乳腺癌干细胞活性与多药耐药的相关性[J].中国组织工程研究,2016,20(32): 4758-4763.[20] 郭锰,万里新.乳腺癌干细胞分离及耐药蛋白分析[J].中国组织工程研究,2015,19(50):8062-8066.[21] 赵益业,蔡宇.补骨脂素逆转人乳腺癌耐药细胞株MCF-7多药耐药性研究[J].中华中医药杂志,2006,21(6):370-371.[22] 于丽丽.补骨脂等三种植物药化学成分研究[D].昆明:云南师范大学,2004.[23] 郭双.试论化浊解毒中药血清及补骨脂素对肝星状细胞生物活性的影响[J].中医临床研究,2015(15):138-139.[24] 蔡宇.补骨脂素逆转白血病HL60/HT耐药细胞研究[J].中成药, 2004,26(9):772-773.[25] Ouaissi A, Ouaissi M, Sereno D. Glutathione S-transferases and related proteins from pathogenic human parasites behave as immunomodulatory factors. Immunol Lett. 2002; 81(3):159-164.[26] Vilchèze C, Jacobs WR Jr. Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis: Genes, Mutations, and Causalities. Microbiol Spectr. 2014; 2(4): MGM2-0014-2013. [27] Ali-Osman F, Brunner JM, Kutluk TM, et al. Prognostic significance of glutathione S-transferase pi expression and subcellular localization in human gliomas. Clin Cancer Res. 1997;3(12 Pt 1):2253-2261.[28] Goto S, Ihara Y, Urata Y, et al. Doxorubicin-induced DNA intercalation and scavenging by nuclear glutathione S-transferase pi. FASEB J. 2001;15(14):2702-2714.[29] Alpert LC, Schecter RL, Berry DA, et al. Relation of glutathione S-transferase alpha and mu isoforms to response to therapy in human breast cancer. Clin Cancer Res. 1997; 3(5):661-667.[30] Kamada K, Goto S, Okunaga T, et al. Nuclear glutathione S-transferase pi prevents apoptosis by reducing the oxidative stress-induced formation of exocyclic DNA products. Free Radic Biol Med. 2004;37(11):1875-1884.[31] Arranz L, Caamaño JH, Lord JM, et al. Preserved immune functions and controlled leukocyte oxidative stress in naturally long-lived mice: possible role of nuclear factor kappa B. J Gerontol A Biol Sci Med Sci. 2010;65(9):941-950. [32] Lee JR, Seok CJ, Kim JS, et al. Expression of NF-kappaB and cytokines in chronic rejection of transplanted murine heart. J Korean Med Sci. 2001;16(4):397-406.[33] Zhao N, Wang R, Zhou L, et al. MicroRNA-26b suppresses the NF-κB signaling and enhances the chemosensitivity of hepatocellular carcinoma cells by targeting TAK1 and TAB3. Mol Cancer. 2014;13:35. [34] 陈进伟,骆蓉,张广森,等.K562/A02耐药细胞NF-κB活性测定及葛根素部分逆转耐药效应的初步研究[J].中华血液学杂志,2006, 27(7):482-484.[35] Dong X, Liu F, Li M. Inhibition of nuclear factor κB transcription activity drives a synergistic effect of cisplatin and oridonin on HepG2 human hepatocellular carcinoma cells. Anticancer Drugs. 2016;27(4):286-299. [36] Wang X, Cheng K, Han Y, et al. Effects of Psoralen as an Anti-tumor Agent in Human Breast Cancer MCF-7/ADR Cells. Biol Pharm Bull. 2016;39(5):815-822.[37] Li J, Xu LZ, He KL, et al. Reversal effects of nomegestrol acetate on multidrug resistance in adriamycin-resistant MCF7 breast cancer cell line. Breast Cancer Res. 2001;3(4):253- 263. [38] Cheng YH, Qi J, Xiong DS, et al. Reversal of multidrug resistance in drug-resistant human breast cancer cell line MCF-7/ADR by calmodulin antagonist O-(4-ethoxyl-butyl)- berbamine. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2006; 28(2):164-168. [39] Li F, Fan J, Wu Z, et al. Reversal effects of Rabdosia rubescens extract on multidrug resistance of MCF-7/Adr cells in vitro. Pharm Biol. 2013;51(9):1196-1203. [40] Tsou SH, Hou MH, Hsu LC, et al. Gain-of-function p53 mutant with 21-bp deletion confers susceptibility to multidrug resistance in MCF-7 cells. Int J Mol Med. 2016;37(1):233-242.[41] Kim HG, Hien TT, Han EH, et al. Metformin inhibits P-glycoprotein expression via the NF-κB pathway and CRE transcriptional activity through AMPK activation. Br J Pharmacol. 2011;162(5):1096-1108. [42] Tsou SH, Chen TM, Hsiao HT, et al. A critical dose of doxorubicin is required to alter the gene expression profiles in MCF-7 cells acquiring multidrug resistance. PLoS One. 2015; 10(1):e0116747. [43] Wang TX, Yang XH. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells. Yao Xue Xue Bao. 2008; 43(5):461-466. [44] Jiang J, Wang X, Cheng K, et al. Psoralen reverses the P-glycoprotein-mediated multidrug resistance in human breast cancer MCF-7/ADR cells. Mol Med Rep. 2016;13(6): 4745-4750. |